Catégorie : Neurobiologie

Cannabis sativa L. as a Natural Drug Meeting the Criteria of a Multitarget Approach to Treatment, Anna Stasiłowicz et al., 2021

Cannabis sativa L. as a Natural Drug Meeting the Criteria of a Multitarget Approach to Treatment Anna Stasiłowicz, Anna Tomala, Irma Podolak and Judyta Cielecka-Piontek International Journal of Molecular Sciences, 2021, 22, 778. Doi : 10.3390/ijms22020778 Abstract : Cannabis sativa L. turned out to be a valuable source of chemical compounds of various structures, showing pharmacological activity. The most important groups of compounds include phytocannabinoids and terpenes. The pharmacological activity of Cannabis (in epilepsy, sclerosis multiplex (SM), vomiting and nausea, pain, appetite loss, inflammatory bowel diseases (IBDs), Parkinson’s disease, Tourette’s syndrome, schizophrenia, glaucoma, and coronavirus disease 2019 (COVID-19)), which has been proven so far, results [...]

Lire la suite

Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol, Douglas L Boggs et al., 2018

Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol Douglas L Boggs, Jacques D Nguyen, Daralyn Morgenson, Michael A Taffe and Mohini Ranganathan Neuropsychopharmacology Reviews, 2018, 43, 142–154. doi : 10.1038/npp.2017.209; The plant Cannabis sativa, commonly called cannabis or marijuana, has been used for its psychotropic and mind-altering side effects for millennia. There has been growing attention in recent years on its potential therapeutic efficacy as municipalities and legislative bodies in the United States, Canada, and other countries grapple with enacting policy to facilitate the use of cannabis or its constituents for medical purposes. There are 4550 chemical compounds and 4100 phytocannabinoids [...]

Lire la suite

Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca, Nicole Leite Galvão-Coelho et al., 2020

Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca Nicole Leite Galvão-Coelho, Ana Cecília de Menezes Galvão, Raíssa Nóbrega de Almeida, Fernanda Palhano-Fontes, Isaac Campos Braga, Bruno Lobão Soares, João Paulo Maia-de-Oliveira, Daniel Perkins, Jerome Sarris and Draulio Barros de Araujo Journal of Psychopharmacology, 2020, 1-9. DOI : 10.1177/0269881120936486   Abstract Background : Ayahuasca is a traditional Amazon brew and its potential antidepressant properties have recently been explored in scientific settings. We conducted a double-blind placebo-controlled trial of ayahuasca with treatment-resistant depression patients (n = 28) and healthy controls (n = 45). Aims : We are evaluating the blood inflammatory biomarkers: C-reactive protein and [...]

Lire la suite

Neuroprotection Following Concussion : The Potential Role for Cannabidiol, Jyotpal Singh, John Patrick Neary, 2020

Neuroprotection Following Concussion : The Potential Role for Cannabidiol Jyotpal Singh, John Patrick Neary Canadian Journal of Neurological Sciences, 2020,  1–12 doi : 10.1017/cjn.2020.23   ABSTRACT : Cannabidiol (CBD) has been generating increasing interest in medicine due to its therapeutic properties and an apparent lack of negative side effects. Research has suggested that high dosages of CBD can be taken acutely and chronically with little to no risk. This review focuses on the neuroprotective effects of a CBD, with an emphasis on its implications for recovering from a mild traumatic brain injury (TBI) or concussion. CBD has been shown to influence the endocannabinoid system, both by [...]

Lire la suite

Add-On Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex. A Placebo-Controlled Randomized Clinical Trial, Elizabeth A. Thiele et al., 2020

Add-On Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex. A Placebo-Controlled Randomized Clinical Trial Elizabeth A. Thiele, MD, PhD; E. Martina Bebin, MD, MPA; Hari Bhathal, MD; Floor E. Jansen, MD; Katarzyna Kotulska, MD, PhD; John A. Lawson, BMed, PhD; Finbar J. O'Callaghan, MBChB, PhD; MichaelWong,MD, PhD; Farhad Sahebkar, MD; Daniel Checketts, MSc; Volker Knappertz, MD; for the GWPCARE6 Study Group JAMA Neurology, 2020, December 21 online, E1-E7. doi : 10.1001/jamaneurol.2020.4607   IMPORTANCE : Efficacy of cannabidiol has been demonstrated in seizures associated with Lennox-Gastaut and Dravet syndromes but appears not yet to have been established in conditions with primarily focal seizures, such as [...]

Lire la suite

Bibliographie : Cannabinoïdes synthétiques et Néocannabinoïdes, Dr Christian Sueur, GRECC, décembre 2020

Bibliographie : Cannabinoïdes synthétiques et Néocannabinoïdes   Dr Christian Sueur, GRECC, décembre 2020   Définitions et Usages des cannabinoïdes synthétiques : 2 - 6 Toxicologie des cannabinoïdes synthétiques : 7– 12 Cannabinoïdes synthétiques et psychose : 11 - 12 Pharmacologie des cannabinoïdes synthétiques : 13 - 16 Neurophysiologie des cannabinoïdes synthétiques : 17 -18 Analyse des cannabinoïdes synthétiques : 18 - 19 Usage médical des cannabinoïdes synthétiques : 20 – 22 Rimonabant : 21 -22  

Lire la suite

Bibliographie : Cannabis et Cannabinoides en Psychiatrie, Docteur Christian Sueur, GRECC, décembre 2020

Bibliographie : Cannabis et Cannabinoides en Psychiatrie   Docteur Christian Sueur, GRECC, décembre 2020. (4e version, décembre 2020....)   1 - Généralités : 1 - 11 2 -Cannabinoïdes et anxiété : 12 3 - Cannabidiol anxiolytique : 13 - 15 4 - Cannabidiol antipsychotique : 16 - 21 5 - Cannabinoïdes et dépression : 22 - 28 6 - Cannabidiol antidépresseur : 29 7 - Cannabinoïdes et Sommeil : 30 - 31 8 - Cannabinoïdes et addiction au Cannabis : 32 - 39 9 - Cannabinoïdes et addictions (cocaine, opiacés, amphétamines, alcool, tabac) : 40 - 54 10 - Cannabinoides et syndrome de Gilles de la Tourette : 58 - 59 11 - Cannabinoides et Hyperactivité [...]

Lire la suite

The potential synergistic effects between psychedelic administration and nature contact for the improvement of mental health, Sam Gandy et al, 2020

The potential synergistic effects between psychedelic administration and nature contact for the improvement of mental health Sam Gandy, Matthias Forstmann, Robin Lester Carhart-Harris, Christopher Timmermann, David Luke and Rosalind Watts Health Psychology Open, 2020, 1–21 Doi : 10.1177/2055102920978123   Abstract Therapeutic psychedelic administration and contact with nature have been associated with the same psychological mechanisms : decreased rumination and negative affect, enhanced psychological connectedness and mindfulness related capacities, and heightened states of awe and transcendent experiences, all processes linked to improvements in mental health amongst clinical and healthy populations. Nature-based settings can have inherently psychologically soothing properties which may complement all stages of psychedelic therapy (mainly [...]

Lire la suite

Effects of external stimulation on psychedelic state neurodynamics, Pedro A.M. Mediano et al., 2020

Effects of external stimulation on psychedelic state neurodynamics Pedro A.M. Mediano, Fernando E. Rosas, Christopher Timmermann, Leor Roseman, David J. Nutt, Amanda Feilding, Mendel Kaelen, Morten L. Kringelbach, Adam B. Barretti, Anil K. Seth, Suresh Muthukumaraswamy, Daniel Bor, and Robin L. Carhart-Harris bioRxiv preprint, 2020 doi : 10.1101/2020.11.01.356071   Abstract Recent findings have shown that psychedelics reliably enhance brain entropy (understood as neural signal diversity), and this effect has been associated with both acute and long-term psychological outcomes such as personality changes. These findings are particularly intriguing given that a decrease of brain entropy is a robust indicator of loss of consciousness (e.g. from wakefulness to [...]

Lire la suite

Troubles anxieux : le CBD peut soulager les symptômes, Kalapa Clinic, 30/06/2020

Troubles anxieux : le CBD peut soulager les symptômes Kalapa Clinic, Barcelone, Espagne By Gesa|30/06/2020   La peur est une réaction naturelle à certaines situations et à certains événements. Elle remplit à la fois une fonction d’avertissement et de protection. Lors d’un trouble anxieux, cependant, elle développe une dynamique propre qui est très stressante pour les personnes concernées. Diverses études et rapports d’expérience indiquent que le cannabinoïde non-psychoactif cannabidiol (CBD) peut soulager leurs symptômes. En Allemagne, le trouble anxieux est la maladie mentale la plus courante, devançant même la dépression. Environ 12 millions de personnes sont touchées, les femmes plus souvent que les hommes (1). Le [...]

Lire la suite